1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
The link for this program now points to a previous cycle.
Historical funding: Varies by project phase (Phase I and Phase II)
Prior eligibility: Small business concerns (SBCs) developing technologies for commercialization.
Seeking Products to Address Social Needs impacting Substance Use Disorders (SUD) (R43/R44 Clinical Trial Optional) is sponsored by National Institute on Drug Abuse (NIDA) and other NIH Institutes, Centers, and Offices. This opportunity supports mission-aligned projects and measurable outcomes.
The HEAL Initiative's Studies to Enable Analgesic Discovery award (RFA-NS-25-023) puts federal money exactly where private capital won't go — the assay-building, screening, and hit-characterization stage of non-opioid pain therapeutics. It's a phased R61/R33, up to $350,000 in direct costs per year, with the next application deadline September 17, 2026. Here is how the two-phase structure works, who's eligible, and how to build a proposal that survives the R61-to-R33 milestone gate.
Read articleARPA-H launched SPECTRA on September 17, 2026 under solicitation ARPA-H-SOL-26-163 — four technical areas with separate Solution Summary deadlines on October 18, December 2, and January 18. The enabling-technologies area closes first, five weeks after launch. Here is why the sequencing matters and how to read each TA.
Read articlePA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read article